Ypsomed Holding AG
SIX:YPSN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
292
437
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one YPSN stock under the Base Case scenario is 434.69 CHF. Compared to the current market price of 357 CHF, Ypsomed Holding AG is Undervalued by 18%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ypsomed Holding AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for YPSN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Ypsomed Holding AG
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Ypsomed Holding AG is a Swiss-based medical technology company that has carved out a niche in the rapidly growing diabetes management and drug delivery market. Founded in 1984, the company initially focused on producing insulin delivery systems but has since expanded its portfolio to include sophisticated pens and pumps that facilitate self-administration of medications. With an emphasis on innovation and user-centered design, Ypsomed has positioned itself as a leader in the development of advanced delivery systems that cater to the evolving needs of patients and healthcare providers alike. The company’s strategic partnerships with pharmaceutical firms enhance its growth trajectory, undersco...
Ypsomed Holding AG is a Swiss-based medical technology company that has carved out a niche in the rapidly growing diabetes management and drug delivery market. Founded in 1984, the company initially focused on producing insulin delivery systems but has since expanded its portfolio to include sophisticated pens and pumps that facilitate self-administration of medications. With an emphasis on innovation and user-centered design, Ypsomed has positioned itself as a leader in the development of advanced delivery systems that cater to the evolving needs of patients and healthcare providers alike. The company’s strategic partnerships with pharmaceutical firms enhance its growth trajectory, underscoring its commitment to improving patient outcomes and fostering adherence to treatment regimens.
As an investor, you’ll appreciate Ypsomed’s robust financial performance, characterized by consistent revenue growth and a solid balance sheet. The company not only serves a significant portion of the diabetic population but also capitalizes on the increasing demand for self-medication and chronic disease management solutions. With a keen focus on research and development, Ypsomed is well-prepared to leverage trends in digital health and personalized medicine. Its global market presence, combined with a dedication to sustainability and innovation, positions Ypsomed as a compelling investment opportunity in a healthcare sector that is both resilient and essential. Ultimately, Ypsomed's commitment to transforming healthcare through advanced technology makes it an appealing choice for investors looking to tap into the future of medical devices.
Ypsomed Holding AG is a Swiss medical technology company primarily focused on the development, production, and distribution of injection and infusion systems for diabetes and other chronic diseases. The core business segments of Ypsomed can be classified as follows:
-
Diabetes Care: This segment is the core of Ypsomed's business, focusing on the development of products for the management of diabetes. It includes pen systems for insulin delivery, continuous glucose monitoring systems, and disposable and reusable insulin pens. Ypsomed aims to improve the quality of life for diabetic patients through innovative solutions.
-
Drug Delivery Systems: Ypsomed provides customized drug delivery systems for pharmaceutical companies, which includes prefilled syringes, autoinjectors, and wearable injectors. This segment is focused on delivering medications for chronic conditions, including but not limited to diabetes.
-
Contract Manufacturing: Ypsomed offers contract manufacturing services for medical technology and pharmaceutical companies. This involves producing devices, components, and systems tailored to specific client needs, thereby leveraging its expertise in manufacturing high-quality medical devices.
-
Digital Health Services: Recognizing the importance of technology in healthcare, Ypsomed has ventured into digital health, offering solutions that integrate with their devices. This includes digital platforms and applications that assist patients in managing their health conditions more effectively.
These segments reflect Ypsomed's commitment to enhancing treatment adherence and patient outcomes, positioning the company as a leader in the medical technology sector.
Ypsomed Holding AG, a Swiss company specializing in the development and production of injection and infusion systems for self-medication, has several unique competitive advantages that differentiate it from its rivals. Here are some key aspects:
-
Innovative Product Portfolio: Ypsomed is known for its focus on innovative and user-friendly drug delivery systems, including autoinjectors and infusion systems. This emphasis on innovation allows the company to meet the evolving needs of patients and healthcare providers.
-
Strong R&D Capabilities: The company invests significantly in research and development, which enables it to stay ahead of technological advancements in drug delivery. Their established R&D capabilities help them adapt quickly to market changes and customer needs.
-
Partnerships and Collaborations: Ypsomed has formed strategic partnerships with major pharmaceutical companies, enhancing its credibility and extending its market reach. These collaborations often lead to joint development projects that align with customer requirements.
-
Customization and Flexibility: Ypsomed offers tailored solutions for its clients, which is crucial in the pharmaceutical industry where a one-size-fits-all approach is often insufficient. This ability to customize products according to client specifications can create stronger customer loyalty.
-
Regulatory Expertise: Ypsomed’s deep understanding of regulatory environments across different countries enables it to navigate complex approval processes more effectively than many competitors, thus speeding up time to market.
-
Focus on Patient-Centric Solutions: The company prioritizes user-friendly designs and ergonomic products that enhance the patient experience. By incorporating feedback from patients and healthcare professionals, Ypsomed can develop solutions that improve adherence and outcomes.
-
Strong Brand Reputation: Ypsomed has built a solid reputation for quality and reliability, which can be a significant factor in business-to-business relationships in the pharmaceutical sector. This reputation helps attract and retain clients in a competitive market.
-
Vertical Integration: Ypsomed maintains a level of vertical integration by controlling various aspects of the supply chain, from design to production. This integration can lead to efficiencies and better quality control compared to competitors who rely heavily on third-party suppliers.
-
Experienced Management Team: The leadership team possesses extensive experience not only in the medical technology field but also in business development and strategic partnerships. This expertise supports effective decision-making and long-term planning.
In summary, Ypsomed's unique competitive advantages stem from its innovative approach, strong partnerships, customization capabilities, regulatory expertise, patient-centric focus, and the overall reputation and experience of its management team. These factors collectively position the company favorably within the competitive landscape of the medical device industry.
Ypsomed Holding AG, a Swiss company specializing in the development and manufacturing of injection and infusion systems for self-medication, faces several risks and challenges in the near future:
-
Regulatory Risks: The medical device and pharmaceutical sectors are heavily regulated. Changes in regulations, increased scrutiny from regulatory bodies, or delays in product approvals can impact Ypsomed's operations and product launch timelines.
-
Competition: The market for drug delivery systems is highly competitive, with numerous players, including large pharmaceutical companies and specialized firms. Increased competition can lead to pricing pressures and a loss of market share.
-
Technological Advancements: The rapid pace of technological development in drug delivery and medical devices requires continuous innovation. Ypsomed must invest in R&D to keep pace, and failure to do so could render its products obsolete.
-
Supply Chain Disruptions: Global supply chain challenges, exacerbated by geopolitical tensions and the COVID-19 pandemic, can affect the availability and cost of raw materials, impacting production timelines and costs.
-
Market Demand Fluctuations: Demand for self-medication devices can be influenced by healthcare trends, economic conditions, and changes in patient preferences. Economic downturns or shifts towards alternative treatments may affect sales.
-
Intellectual Property Risks: Protecting intellectual property is crucial in the medical device industry. Patent infringements or the expiration of key patents could open the market to competitors and affect Ypsomed's revenue.
-
Partnership and Collaboration Risks: Ypsomed collaborates with pharmaceutical companies for the development of combination products. Any issues in these partnerships, such as misalignment of goals or failure to deliver, can impact product development and commercialization.
-
Cybersecurity Threats: As medical devices increasingly incorporate digital technologies, the risk of cybersecurity incidents becomes a concern. A data breach or cyberattack could compromise patient safety and company reputation.
-
Economic Factors: Global economic conditions, including inflation and currency fluctuations, can affect Ypsomed's profitability, particularly if they operate in multiple currency zones.
-
Talent Acquisition and Retention: Attracting and retaining skilled professionals, particularly in engineering, R&D, and compliance, is essential for innovation and growth. Labor shortages can hinder progress.
To mitigate these risks, Ypsomed should implement robust risk management strategies, continue to innovate its product lines, and maintain strong partnerships in the industry. Regular market analysis and a proactive approach toward regulatory changes will also be crucial in navigating the challenges ahead.
Revenue & Expenses Breakdown
Ypsomed Holding AG
Balance Sheet Decomposition
Ypsomed Holding AG
Current Assets | 341.1m |
Cash & Short-Term Investments | 52.3m |
Receivables | 130.5m |
Other Current Assets | 158.2m |
Non-Current Assets | 839.9m |
Long-Term Investments | 2.7m |
PP&E | 495.2m |
Intangibles | 305.3m |
Other Non-Current Assets | 36.7m |
Current Liabilities | 513.4m |
Accounts Payable | 25.1m |
Accrued Liabilities | 59.7m |
Short-Term Debt | 325.2m |
Other Current Liabilities | 103.4m |
Non-Current Liabilities | 45.8m |
Other Non-Current Liabilities | 45.8m |
Earnings Waterfall
Ypsomed Holding AG
Revenue
|
617.1m
CHF
|
Cost of Revenue
|
-398.4m
CHF
|
Gross Profit
|
218.7m
CHF
|
Operating Expenses
|
-131.8m
CHF
|
Operating Income
|
86.8m
CHF
|
Other Expenses
|
-12.5m
CHF
|
Net Income
|
74.4m
CHF
|
Free Cash Flow Analysis
Ypsomed Holding AG
CHF | |
Free Cash Flow | CHF |
YPSN Profitability Score
Profitability Due Diligence
Ypsomed Holding AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Ypsomed Holding AG's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
YPSN Solvency Score
Solvency Due Diligence
Ypsomed Holding AG's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Ypsomed Holding AG's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YPSN Price Targets Summary
Ypsomed Holding AG
According to Wall Street analysts, the average 1-year price target for YPSN is 433.09 CHF with a low forecast of 329.26 CHF and a high forecast of 519.75 CHF.
Dividends
Current shareholder yield for YPSN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
YPSN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. The company is headquartered in Burgdorf, Bern and currently employs 1,900 full-time employees. The company went IPO on 2004-09-22. The firm develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The firm operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The firm operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Contact
IPO
Employees
Officers
The intrinsic value of one YPSN stock under the Base Case scenario is 434.69 CHF.
Compared to the current market price of 357 CHF, Ypsomed Holding AG is Undervalued by 18%.